The elevated expression of haemoxygenase, which is an Nrf1/2 dependent gene, as a result of PB treatment in BRCA1 blocked BG1 ovarian cancer cell has also been reported earlier by our own group, confirming the activation of the antioxidant mechanism9. This evidence concerns the gene NRF1 and ovarian carcinoma.